From WikiProjectMed
Jump to navigation Jump to search
Trade namesPurinethol, Purixan, others
Other names6-mercaptopurine (6-MP)
  • 3,7-dihydropurine-6-thione
Clinical data
Drug classAntimetabolite[1][2]
Main usesCancer, ulcerative colitis[3]
Side effectsBone marrow suppression, liver toxicity, vomiting, loss of appetite[3]
  • D
Routes of
By mouth
Defined daily doseNot established[4]
External links
License data
Legal status
  • In general: ℞ (Prescription only)
Bioavailability5 to 37%
Metabolismxanthine oxidase
Elimination half-life60 to 120 min., longer for its active metabolites
Chemical and physical data
Molar mass152.18 g·mol−1
3D model (JSmol)
  • S=c1nc[nH]c2nc[nH]c12
  • InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10) checkY

Mercaptopurine (6-MP), sold under the brand name Purinethol among others, is a medication used for cancer and autoimmune diseases.[3] Specifically it is used to treat acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.[3][2] For acute lymphocytic leukemia it is generally used with methotrexate.[3] It is taken by mouth.[3]

Common side effects include bone marrow suppression, liver toxicity, vomiting, and loss of appetite.[3] Other serious side effects include an increased risk of future cancer and pancreatitis.[3] Those with a genetic deficiency in thiopurine S-methyltransferase are at higher risk of side effects.[3] Use in pregnancy may harm the baby.[3] Mercaptopurine is in the thiopurine and antimetabolite family of medications.[1][2]

Mercaptopurine was approved for medical use in the United States in 1953.[3] It is on the World Health Organization's List of Essential Medicines.[5] The wholesale cost in the developing world is about US$18.42–200.16 a month.[6] In the United Kingdom this costs the NHS about 121 pounds per month.[2] In the United States the wholesale cost is about $100 per month as of 2016.[7]

Medical uses

It is used to treat acute lymphocytic leukemia, Crohn's disease, and ulcerative colitis.[8]


The defined daily dose is not established.[4]

Side effects

Some of the adverse reactions of taking mercaptopurine may include diarrhea, nausea, vomiting, loss of appetite, fatigue, stomach/abdominal pain, weakness, skin rash, darkening of the skin, and hair loss. Serious adverse reactions include mouth sores, fever, sore throat, easy bruising or bleeding, pinpoint red spots on the skin, yellowing of eyes or skin, dark urine, and painful or difficult urination. Other more serious side effects include black or tarry stools (melena), bloody stools, and bloody urine.

Symptoms of allergic reaction to mercaptopurine include rash, itching, swelling, dizziness, trouble breathing, and inflammation of the pancreas.

In some cases, mercaptopurine may suppress the production of blood cells, both white blood cells and red blood cells. It may be toxic to bone marrow. Quarterly blood counts are necessary for people on mercaptopurine. People should stop taking the medication at least temporarily while considering alternate treatment if there is an unexplained, abnormally large drop in white blood cell count, or any other blood count.

Toxicity of mercaptopurine can be linked to genetic polymorphisms in thiopurine S-methyltransferase (TPMT), nudix hydrolase 15(NUDT15),[9][10] and inosine triphosphate pyrophosphatase (ITPA). People with specific allele variants will require dose adjustments, especially for those with homozygous variant genotypes. Large differences of TPMT and NUDT15 among ethnicities in terms of variant allele frequency should be taken into consideration in clinical practice.[11] Caucasian people with a variant allele of the ITPA gene, experience higher rates of febrile neuropenia than people of other ethnic groups, due to differences in allelic frequencies among ethnicities.[12]


Mercaptopurine can lower the body's ability to fight off infection. Those taking it should get permission from a doctor to receive immunizations and vaccinations. It is also recommended that, while on the drug, one should avoid those having recently received oral polio vaccine.

This drug was formerly not recommended during pregnancy and early evidence indicated pregnant women on the drug (or the related azathioprine) showed a seven-fold incidence of fetal abnormalities as well as a 20-fold increase in miscarriage.[13] There were also anecdotal reports linking mercaptopurine with spontaneous abortion, leading to the US FDA rating both AZA and mercaptopurine as category D drugs. However, Davis et al. 1999 found mercaptopurine, compared to methotrexate, was ineffective as a single-agent abortifacient; every woman in the mercaptopurine arm of the study had fetal cardiac activity at follow-up (two weeks later) and was given a suction abortion.[14] A more recent, larger study, however, performed by the Cancers et Surrisque Associe aux Maladies inflamatoires intestinales En France (CESAME) indicated an overall rate of congenital malformations not significantly greater than the general population in France.[15] The European Crohn's and Colitis Organisation (ECCO) concluded in a consensus paper in 2010 that while AZA and mercaptopurine have an FDA rating of D, new research in both animals and humans indicates that "thiopurines are safe and well tolerated during pregnancy."[16]

Mercaptopurine causes changes to chromosomes in animals and humans, though a study in 1990[17] found, "while the carcinogenic potential of 6-MP cannot be precluded, it can be only very weak or marginal." Another study in 1999[18] noted an increased risk of developing leukemia when taking large doses of 6-MP with other cytotoxic drugs.

Drug interactions

Allopurinol inhibits xanthine oxidase, the enzyme that breaks down mercaptopurine. Those taking allopurinol (often used to prevent gout) are at risk for mercaptopurine toxicity. The dose should be reduced or allopurinol should be discontinued. Several published studies have demonstrated that the use of allopurinol in combination with low dose 6-MP helps reduce 6-MP levels, which are toxic to liver tissue, whilst increasing the therapeutic levels of 6-MP for some inflammatory conditions.

Mechanisms of action

Official information from the package insert for purinethol:[19]

  • Mercaptopurine (6-MP) competes with the purine derivatives hypoxanthine and guanine for the enzyme HGPRT and is itself converted to thio inosine monophosphate (TIMP).
    • TIMP inhibits several chemical reactions involving inosinic acid (IMP), including the conversion of IMP to xanthylic acid (XMP) and the conversion of IMP to adenylic acid (AMP) via adenylosuccinate (SAMP).
    • In addition, 6-methylthioinosinate (MTIMP) is formed by the methylation of TIMP.
      • Both TIMP and MTIMP have been reported to inhibit glutamine-5-phosphoribosylpyrophosphate amidotransferase, the first enzyme unique to the de novo pathway for purine ribonucleotide synthesis. Experiments indicate that radiolabeled mercaptopurine may be recovered from the DNA in the form of deoxythioguanosine.
  • Some mercaptopurine is converted to nucleotide derivatives of 6-thioguanine (6-TG) by the sequential actions of inosinate (IMP) dehydrogenase and xanthylate (XMP) aminase, converting TIMP to thioguanylic acid (TGMP).
  • Animal tumors that are resistant to mercaptopurine often have lost the ability to convert mercaptopurine to TIMP. However, it is clear that resistance to mercaptopurine may be acquired by other means as well, particularly in human leukemias.
  • It is not known exactly which of any one or more of the biochemical effects of mercaptopurine and its metabolites are directly or predominantly responsible for cell death.

6-MP ribonucleotide inhibits purine nucleotide synthesis and metabolism by inhibiting an enzyme called phosphoribosyl pyrophosphate amidotransferase (PRPP amidotransferase). Since this enzyme is the rate limiting factor for purine synthesis,[20] this alters the synthesis and function of RNA and DNA.[citation needed] Mercaptopurine interferes with nucleotide interconversion and glycoprotein synthesis.


The enzyme thiopurine S-methyltransferase (TPMT) is responsible, in part, for the inactivation of 6-mercaptopurine. TPMT catalyzes the methylation of 6-mercaptopurine into the inactive metabolite 6-methylmercaptopurine – this methylation prevents mercaptopurine from further conversion into active, cytotoxic thioguanine nucleotide (TGN) metabolites.[21][22][23] Certain genetic variations within the TPMT gene can lead to decreased or absent TPMT enzyme activity, and individuals who are homozygous or heterozygous for these types of genetic variations may have increased levels of TGN metabolites and an increased risk of severe bone marrow suppression (myelosuppression) when receiving mercaptopurine.[24] In many ethnicities, TPMT polymorphisms that result in decreased or absent TPMT activity occur with a frequency of approximately 5%, meaning that about 0.25% of people are homozygous for these variants.[24][25] However, an assay of TPMT activity in red blood cells or a TPMT genetic test can identify people with reduced TPMT activity, allowing for the adjustment of mercaptopurine dose or avoidance of the drug entirely.[24][26] The FDA-approved drug label for mercaptopurine recommends testing for TPMT activity to identify people at risk for myelotoxicity.[27][28] Testing for TPMT activity is an example of pharmacogenetics being translated into routine clinical care.[29]


6-MP was discovered by Nobel Prize winning scientists Gertrude B. Elion and George H. Hitchings at Burroughs Wellcome in Tuckahoe, New York,[30] and was clinically developed in collaboration with investigators at Memorial Hospital (now Memorial Sloan Kettering Cancer Center in New York City).[31] The collaboration was initiated by Cornelius P. Rhoads who had run chemical weapons programs for the US army and had been involved in the work that led to the discovery that nitrogen mustards could potentially be used as cancer drugs, and had become the director of Memorial in 1948.[31]

See also


  1. 1.0 1.1 Sahasranaman, S.; Howard, D.; Roy, S. (2008). "Clinical pharmacology and pharmacogenetics of thiopurines". European Journal of Clinical Pharmacology. 64 (8): 753–767. doi:10.1007/s00228-008-0478-6. PMID 18506437. S2CID 27475772.
  2. 2.0 2.1 2.2 2.3 British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 590. ISBN 9780857111562.
  3. 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 "Mercaptopurine". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
  4. 4.0 4.1 "WHOCC - ATC/DDD Index". Archived from the original on 15 September 2020. Retrieved 17 September 2020.
  5. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  6. "Mercaptopurine". International Drug Price Indicator Guide. Archived from the original on 22 January 2018. Retrieved 8 December 2016.
  7. "NADAC as of 2016-12-07 |". Centers for Medicare and Medicaid Services. Archived from the original on 21 December 2016. Retrieved 21 December 2016.
  8. "Mercaptopurine". The American Society of Health-System Pharmacists. Archived from the original on 2015-09-06. Retrieved Aug 28, 2015.
  9. Yang, JJ; Landier, W; Yang, W; Liu, C; Hageman, L; Cheng, C; Pei, D; Chen, Y; Crews, KR; Kornegay, N; Wong, FL; Evans, WE; Pui, CH; Bhatia, S; Relling, MV (10 April 2015). "Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia". Journal of Clinical Oncology. 33 (11): 1235–42. doi:10.1200/jco.2014.59.4671. PMC 4375304. PMID 25624441.
  10. Moriyama, T; Nishii, R; Perez-Andreu, V; Yang, W; Klussmann, FA; Zhao, X; Lin, TN; Hoshitsuki, K; Nersting, J; Kihira, K; Hofmann, U; Komada, Y; Kato, M; McCorkle, R; Li, L; Koh, K; Najera, CR; Kham, SK; Isobe, T; Chen, Z; Chiew, EK; Bhojwani, D; Jeffries, C; Lu, Y; Schwab, M; Inaba, H; Pui, CH; Relling, MV; Manabe, A; Hori, H; Schmiegelow, K; Yeoh, AE; Evans, WE; Yang, JJ (April 2016). "NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity". Nature Genetics. 48 (4): 367–73. doi:10.1038/ng.3508. PMC 5029084. PMID 26878724.
  11. Yin, D; Xia, X; Zhang, J; Zhang, S; Liao, F; Zhang, G; Zhang, Y; Hou, Q; Yang, X; Wang, H; Ma, Z; Wang, H; Zhu, Y; Zhang, W; Wang, Y; Liu, B; Wang, L; Xu, H; Shu, Y (21 February 2017). "Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose". Oncotarget. 8 (8): 13575–13585. doi:10.18632/oncotarget.14594. PMC 5355121. PMID 28088792.
  12. Esses, S. I.; Morley, T. P. (1983). "Spinal arachnoiditis". The Canadian Journal of Neurological Sciences. 10 (1): 2–10. doi:10.1017/s0317167100044486. PMID 6404543.
  13. Nørgård, B.; L. Pedersen; K. Fonager; S. Rasmussen; H. Sørensen (March 2003). "Azathioprine, mercaptopurine and birth outcome: a population-based cohort study". Alimentary Pharmacology & Therapeutics. 17 (6): 827–834. doi:10.1046/j.1365-2036.2003.01537.x. PMID 12641505.
  14. Davis, Anne R.; Leslie Miller; Hisham Tamimi; Allen Gown (June 1999). "Methotrexate Compared With Mercaptopurine for Early Induced Abortion". Obstetrics & Gynecology. 93 (6): 904–9. doi:10.1016/S0029-7844(98)00569-9. PMID 10362152. Archived from the original on 2006-06-19.
  15. Coelho, J.; L. Beaugerie; J.F. Colombel; X. Hébuterne; E. Lerebours; M. Lémann; P. Baumer; et al. (February 2011). "Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study". Gut. 60 (2): 198–203. doi:10.1136/gut.2010.222893. PMID 21115547. S2CID 25614617.
  16. Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J, et al. (February 2010). "The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations". Journal of Crohn's and Colitis. 4 (1): 63–101. doi:10.1016/j.crohns.2009.09.009. PMID 21122490.
  17. Maekawa, A.; T. Nagaoka; H. Onodera; Y. Matsushima; A. Todate; M. Shibutani; H. Ogasawara; Y. Kodama; Y. Hayashi (May 1990). "Two-year carcinogenicity study of 6-mercaptopurine in F344 rats". Journal of Cancer Research and Clinical Oncology. 116 (3): 245–250. doi:10.1007/BF01612898. PMID 2370249. S2CID 21675626.
  18. Bo J, Schrøder H, Kristinsson J, Madsen B, Szumlanski C, Weinshilboum R, Andersen JB, Schmiegelow K (September 1999). "Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism". Cancer. 86 (6): 1080–6. doi:10.1002/(SICI)1097-0142(19990915)86:6<1080::AID-CNCR26>3.0.CO;2-5. PMID 10491537.
  19. "PURINETHOL (mercaptopurine) tablet [Gate Pharmaceuticals]" (PDF). DailyMed. Gate Pharmaceuticals. August 2012. Archived from the original on 1 January 2014. Retrieved 31 December 2013.
  20. Hansen, Barbara. "Purine and Pyrimidine Metabolism." USMLE STEP 1 Biochemistry and Medical Genetics Lecture Notes. 2010 ed. N.p.: Kaplan, 2010. 288-90. Print.
  21. Zaza G, Cheok M, Krynetskaia N, Thorn C, Stocco G, Hebert JM, McLeod H, Weinshilboum RM, Relling MV, Evans WE, Klein TE, Altman RB (September 2010). "Thiopurine pathway". Pharmcogenet Genomics. 20 (9): 573–4. doi:10.1097/FPC.0b013e328334338f. PMC 3098750. PMID 19952870.
  22. Stocco G, Pelin M, Franca R, De Iudicibus S, Cuzzoni E, Favretto D, Martelossi S, Ventura A, Decorti G (April 2014). "Pharmacogenetics of azathioprine in inflammatory bowel disease: a role for glutathione-S-transferase?". World J Gastroenterol. 20 (13): 3534–41. doi:10.3748/wjg.v20.i13.3534. PMC 3974520. PMID 24707136.
  23. Fujita K, Sasaki Y (August 2007). "Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy". Curr. Drug Metab. 8 (6): 554–62. doi:10.2174/138920007781368890. PMID 17691917. Archived from the original on 2013-01-12.
  24. 24.0 24.1 24.2 Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE (March 2011). "Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing". Clin Pharmacol Ther. 89 (3): 387–91. doi:10.1038/clpt.2010.320. PMC 3098761. PMID 21270794.
  25. Mutschler, Ernst; Schäfer-Korting, Monika (2001). Arzneimittelwirkungen (in German) (8 ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. pp. 107, 936. ISBN 978-3-8047-1763-3.{{cite book}}: CS1 maint: unrecognized language (link)
  26. Payne, K.; Newman, W.; Fargher, E.; Tricker, K.; Bruce, I. N.; Ollier, W. E. R. (2007). "TPMT testing in rheumatology: Any better than routine monitoring?". Rheumatology. 46 (5): 727–729. doi:10.1093/rheumatology/kel427. PMID 17255139.
  27. "Label: Mercaptopurine – mercaptopurine tablet". Archived from the original on 6 October 2015. Retrieved 11 March 2015.
  28. "Purixan suspension". DailyMed. 9 April 2019. Archived from the original on 12 August 2020. Retrieved 9 April 2020.
  29. Wang L, Pelleymounter L, Weinshilboum R, Johnson JA, Hebert JM, Altman RB, Klein TE (June 2010). "Very important pharmacogene summary: thiopurine S-methyltransferase". Pharmacogenet Genomics. 20 (6): 401–5. doi:10.1097/FPC.0b013e3283352860. PMC 3086840. PMID 20154640.
  30. Katherine Bouton for the New York Times. January 29, 1989 The Nobel Pair Archived 2016-10-07 at the Wayback Machine
  31. 31.0 31.1 Mukherjee, Siddhartha (2010). The Emperor of All Maladies: A Biography of Cancer. New York. pp. 91–92. ISBN 978-1439170915.

Further reading

External links

External sites: